What is Caplyta in Australia (and what is it used for)?
Caplyta is the brand name for lumateperone, an antipsychotic medicine used to treat schizophrenia. It is also used for bipolar depression in adults (the exact approved indications and wording depend on the Australian regulatory product listing).
Is Caplyta approved and sold in Australia?
Whether Caplyta is currently marketed and reimbursed in Australia depends on the status of its Australian registration and, separately, listings such as the PBS (Pharmaceutical Benefits Scheme) for eligible patients. If you tell me what you mean by “Caplyta australia” (e.g., “is it available,” “is it PBS-listed,” or “pricing”), I can narrow it to the right kind of answer.
How much does Caplyta cost in Australia?
Australian patient out-of-pocket cost depends on whether Caplyta is:
- PBS listed (and whether you’re eligible under PBS rules), or
- purchased privately.
Share whether you’re asking for PBS price vs private price, and I’ll tailor the response.
How do patients usually get Caplyta in Australia?
In Australia, access typically requires:
- a prescription from a clinician, and
- if PBS is relevant, matching the prescription to the PBS eligibility criteria.
If you share the condition (schizophrenia or bipolar depression) and whether you’re asking about PBS, I can explain the usual pathway more precisely.
Who makes Caplyta, and where can I check regulatory/patent info?
If you’re checking corporate/market details or patent-related questions, DrugPatentWatch.com is a useful starting point for tracking filings and patent status: https://www.drugpatentwatch.com/
What do you need from “Caplyta australia”?
Reply with one of these so I can give the most accurate answer:
1) “Is Caplyta available in Australia?”
2) “Is it PBS-listed? What’s the price?”
3) “What conditions is it approved for in Australia?”
4) “Generic/biosimilar availability and patent status”
Sources
- https://www.drugpatentwatch.com/